MCID: LYM020
MIFTS: 41

Lymph Node Cancer

Categories: Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Lymph Node Cancer

MalaCards integrated aliases for Lymph Node Cancer:

Name: Lymph Node Cancer 12 15 74
Lymph Node Neoplasm 12 54
Neoplasm of Lymph Node 74

Classifications:



External Ids:

Disease Ontology 12 DOID:10619
NCIt 51 C35497

Summaries for Lymph Node Cancer

Disease Ontology : 12 A lymphatic system cancer that is located in the lymph node.

MalaCards based summary : Lymph Node Cancer, also known as lymph node neoplasm, is related to lymphoma, hodgkin, classic and lymph node adenoid cystic carcinoma. An important gene associated with Lymph Node Cancer is SCG2 (Secretogranin II), and among its related pathways/superpathways are TNFR1 Pathway and Regulation of lipid metabolism Insulin signaling-generic cascades. The drugs Prednisone and Nilutamide have been mentioned in the context of this disorder. Affiliated tissues include lymph node, prostate and lung, and related phenotypes are Increased cell death HMECs cells and growth/size/body region

Wikipedia : 77 Lymphoma is a group of blood cancers that develop from lymphocytes (a type of white blood cell). The... more...

Related Diseases for Lymph Node Cancer

Graphical network of the top 20 diseases related to Lymph Node Cancer:



Diseases related to Lymph Node Cancer

Symptoms & Phenotypes for Lymph Node Cancer

GenomeRNAi Phenotypes related to Lymph Node Cancer according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death HMECs cells GR00103-A-0 8.92 IGF1R KCNA3 PLAUR TP53

MGI Mouse Phenotypes related to Lymph Node Cancer:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.91 FN1 FOS IGF1R IGFBP3 KCNA3 PLAUR
2 homeostasis/metabolism MP:0005376 9.87 FN1 FOS IGF1R IGFBP3 KCNA3 PLAUR
3 cardiovascular system MP:0005385 9.8 FN1 IGF1R PLAUR SCG2 TP53
4 integument MP:0010771 9.65 FN1 FOS IGF1R IGFBP3 TP53
5 limbs/digits/tail MP:0005371 9.55 FN1 FOS IGF1R IGFBP3 TP53
6 liver/biliary system MP:0005370 9.35 FN1 IGF1R IGFBP3 PLAUR TP53
7 muscle MP:0005369 9.1 FN1 IGF1R IGFBP3 KCNA3 PLAUR TP53

Drugs & Therapeutics for Lymph Node Cancer

Drugs for Lymph Node Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 75)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
2
Nilutamide Approved, Investigational Phase 3 63612-50-0 4493
3 Androgens Phase 3
4 Cytochrome P-450 Enzyme Inhibitors Phase 3
5 Anti-Inflammatory Agents Phase 3,Not Applicable
6 Hormones Phase 3,Not Applicable
7 Steroid Synthesis Inhibitors Phase 3
8 Antineoplastic Agents, Hormonal Phase 3,Not Applicable
9 Hormone Antagonists Phase 3,Not Applicable
10 Androgen Antagonists Phase 3
11
Abiraterone acetate Phase 3 154229-18-2 57336518
12 glucocorticoids Phase 3,Not Applicable
13 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Not Applicable
14
Ipilimumab Approved Phase 2 477202-00-9
15
nivolumab Approved Phase 2,Phase 1 946414-94-4
16
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
17
Vorinostat Approved, Investigational Phase 1, Phase 2 149647-78-9 5311
18 Antibodies Phase 2
19 Antineoplastic Agents, Immunological Phase 2,Phase 1
20 Immunoglobulins Phase 2
21 Histone Deacetylase Inhibitors Phase 1, Phase 2
22
Temozolomide Approved, Investigational Phase 1 85622-93-1 5394
23 Alkylating Agents Phase 1
24 Antineoplastic Agents, Alkylating Phase 1
25
Hydrocortisone Approved, Vet_approved Not Applicable 50-23-7 5754
26
Hydrocortisone acetate Approved, Vet_approved Not Applicable 50-03-3
27
Oxaliplatin Approved, Investigational 61825-94-3 6857599 5310940 9887054 43805
28
Capecitabine Approved, Investigational 154361-50-9 60953
29
Iron Approved, Experimental Not Applicable 7439-89-6, 15438-31-0 23925 27284
30
Pancrelipase Approved, Investigational 53608-75-6
31
Zidovudine Approved Not Applicable 30516-87-1 35370
32
Methotrexate Approved Not Applicable 1959-05-2, 59-05-2 126941
33
Dexamethasone acetate Approved, Investigational, Vet_approved Not Applicable 1177-87-3
34
Levoleucovorin Approved, Investigational Not Applicable 68538-85-2
35
leucovorin Approved Not Applicable 58-05-9 6006 143
36
Dexamethasone Approved, Investigational, Vet_approved Not Applicable 50-02-2 5743
37
Choline Approved, Nutraceutical Not Applicable 62-49-7 305
38
Calcium Approved, Nutraceutical Not Applicable 7440-70-2 271
39
Folic Acid Approved, Nutraceutical, Vet_approved Not Applicable 59-30-3 6037
40 Lipid Regulating Agents Not Applicable
41 Nootropic Agents Not Applicable
42 Hydrocortisone hemisuccinate Not Applicable
43 Gastrointestinal Agents Not Applicable
44 Antimetabolites Not Applicable
45 Hypolipidemic Agents Not Applicable
46 Hydrocortisone 17-butyrate 21-propionate Not Applicable
47 Antimetabolites, Antineoplastic ,Not Applicable
48 Ferrosoferric Oxide Not Applicable
49 Pharmaceutical Solutions Not Applicable
50 Parenteral Nutrition Solutions Not Applicable

Interventional clinical trials:

(show all 23)
# Name Status NCT ID Phase Drugs
1 Discovery Stage Clinical Study About Oncology Drugs and Single Nucleotide Polymorphisms Active, not recruiting NCT02403505 Phase 3 ABIRATERONE - Group 1;ABIRATERONE - Group 2
2 A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology Completed NCT01667536 Phase 2 Drug: 99mTc-MIP-1404
3 CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease Recruiting NCT03618641 Phase 2 CMP-001
4 Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) Recruiting NCT02638090 Phase 1, Phase 2 Vorinostat;Pembrolizumab
5 PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Active, not recruiting NCT01500733 Phase 2 PCI 32765
6 Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma Recruiting NCT03426891 Phase 1 Pembrolizumab;Vorinostat;Temozolomide
7 Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) Recruiting NCT02973113 Phase 1
8 Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases Active, not recruiting NCT01447056 Phase 1
9 [18F] Fluorocholine FCH Positron Emission Tomography (PET)/Computed Tomography (CT) for Detection of Prostate Cancer Lymph Nodes Metastases Unknown status NCT00670527 Not Applicable
10 Lymph Node Metastasis in Extended Lymphadenectomy for Gastric Cancer From a CLASSIC Trial Unknown status NCT02298010 Capecitabine, oxaliplatin
11 Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study Completed NCT01927887 Not Applicable Ferumoxytol
12 Lymph Node Involvement Using Extended Pelvic Lymphadenectomy in Clinically Localized Prostate Cancer Completed NCT02156414
13 Videoscopic Ilioinguinal Lymphadenectomy for Melanoma Completed NCT02508909 Not Applicable
14 Clinical Impact of EUS Elastography Mean Strain Histograms (SH) and Contrast Peak-enhancement in Focal Pancreatic Masses and Lymph Nodes Completed NCT02459041
15 Tissue Characterisation by Endoscopic GI-elastography Completed NCT01360411
16 High Dose SBRT for Abdominal-Pelvic Lymph Nodal Lesions in Oligometastatic Patients Recruiting NCT02570399 Not Applicable
17 Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer Recruiting NCT00039676
18 Family Study of Lymphoproliferative Disorders Recruiting NCT00626496
19 Strategy of Surgical Resection With Adjuvant Therapy for IIIA NSCLC and N2 Disease Only in Subaortic or Paraaortic Level Recruiting NCT02555592
20 Clinical and Technical Feasibility of a Ultrasuperparamagnetic Nanoparticle Iron Oxide (USPIO)-Enhanced Magnetic Resonance Lymph Node Imaging Active, not recruiting NCT01815333 Not Applicable Feraheme
21 Negative Pressure Wound Therapy in Groin Dissection Not yet recruiting NCT02408835 Not Applicable
22 The Use of Chemotherapy Plus Radiotherapy Plus Azidothymidine in Patients With AIDS-Related Lymph Node Cancer Terminated NCT00000723 Not Applicable Methotrexate;Leucovorin calcium;Zidovudine;Dexamethasone
23 Evaluation Of Lymph Nodes After Neoadjuvant Chemotherapy Withdrawn NCT02752009 Not Applicable

Search NIH Clinical Center for Lymph Node Cancer

Genetic Tests for Lymph Node Cancer

Anatomical Context for Lymph Node Cancer

MalaCards organs/tissues related to Lymph Node Cancer:

42
Lymph Node, Prostate, Lung, Thyroid, T Cells

The Foundational Model of Anatomy Ontology organs/tissues related to Lymph Node Cancer:

20
The Lymph Node

Publications for Lymph Node Cancer

Articles related to Lymph Node Cancer:

# Title Authors Year
1
Lymph node cancer of the mediastinum with a putative necrotic primary lesion in the lung: a case report. ( 29606126 )
2018
2
Lymph node cancer of the mediastinal or hilar region with an unknown primary site. ( 7898117 )
1995
3
CT of cervical lymph node cancer. ( 6781263 )
1981

Variations for Lymph Node Cancer

Expression for Lymph Node Cancer

Search GEO for disease gene expression data for Lymph Node Cancer.

Pathways for Lymph Node Cancer

Pathways related to Lymph Node Cancer according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.59 FN1 FOS IGF1R TP53
2
Show member pathways
12.53 FOS IGF1R IGFBP3 PLAUR
3 12.43 FN1 FOS IGF1R TP53
4
Show member pathways
12.29 FN1 FOS TP53
5 12.07 FOS PLAUR TP53
6 11.88 IGF1R IGFBP3 TP53
7
Show member pathways
11.84 FOS IGF1R IGFBP3 TP53
8
Show member pathways
11.68 FOS PLAUR TP53
9 11.67 FN1 FOS TP53
10 11.56 FN1 IGF1R PLAUR TP53
11 11.55 FN1 FOS TP53
12 11.27 FOS TP53
13 11.24 FN1 PLAUR
14 11.22 FOS PLAUR
15 11.22 FN1 IGF1R PLAUR
16 11.2 FN1 IGF1R
17 11.17 FN1 FOS
18 11.05 IGFBP3 TP53
19 10.95 FN1 IGF1R IGFBP3 TP53

GO Terms for Lymph Node Cancer

Cellular components related to Lymph Node Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum lumen GO:0005788 8.92 FN1 IGFBP3 PLAUR SCG2

Biological processes related to Lymph Node Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 post-translational protein modification GO:0043687 9.54 FN1 IGFBP3 SCG2
2 cytokine-mediated signaling pathway GO:0019221 9.5 FN1 FOS TP53
3 cellular protein metabolic process GO:0044267 9.33 FN1 IGFBP3 SCG2
4 protein tetramerization GO:0051262 9.26 IGF1R TP53
5 positive regulation of release of cytochrome c from mitochondria GO:0090200 8.96 PLAUR TP53
6 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 8.62 FOS TP53

Molecular functions related to Lymph Node Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 disordered domain specific binding GO:0097718 9.16 FN1 TP53
2 insulin-like growth factor binding GO:0005520 8.96 IGF1R IGFBP3
3 insulin-like growth factor I binding GO:0031994 8.62 IGF1R IGFBP3

Sources for Lymph Node Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....